Keith T Flaherty - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Keith T Flaherty's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Keith T Flaherty
Verified
Editor-in-Chief, Clinical Cancer Research
Beats
African American genealogy and history HIV/AIDSCOVID-19 health disparities
What you may not find interesting.
Content
A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma
By Dirk Schadendorf, Reinhard Dummer, Keith T Flaherty, Caroline Robert| Taylor & Francis@ Plain Language SummaryWhat is this summary about? This summary presents the 7-year study results from COLUMBUS part 1, which tested encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®) combined (COMBO group) against encorafenib alone (ENCO group) or vemurafenib (ZELBORAF®) alone (VEMU group) as a treatment for a skin cancer called locally advanced or metastatic BRAF V600-mutant melanoma. What were the results?
By Dennis Chang, Keith T Flaherty, Uciane Scarlett| Citeline Verified A Tale Of Two PipelinesThe Promise And Pitfalls Of IO Exuberance And How To Rethink The Approach To Cancer Innovation21 Jan 2020 • By Dennis Chang, Keith Flaherty, and Uciane ScarlettImmuno-oncology has produced some exciting successes, but the field has become intensely crowded. Enormous resources are being poured into duplicative work and shaky hypotheses—overshadowing other pursuits in cancer research while producing limited results.
A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma
By Dirk Schadendorf, Reinhard Dummer, Keith T Flaherty, Caroline Robert| Taylor & Francis@ Plain Language SummaryWhat is this summary about? This summary presents the 7-year study results from COLUMBUS part 1, which tested encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®) combined (COMBO group) against encorafenib alone (ENCO group) or vemurafenib (ZELBORAF®) alone (VEMU group) as a treatment for a skin cancer called locally advanced or metastatic BRAF V600-mutant melanoma. What were the results?
Company Info
Clinical Cancer Research
Natick, Massachusetts, United States
+1 617-528-8715